PK: Ropivacaine Pharmacokinetics After Erector Spinae Block
Study Details
Study Description
Brief Summary
The primary aim is to evaluate the analgesic efficacy of either technique by measuring cumulative morphine consumption in the first 24 hours after an erector spinae plane block with 2 ml/kg of ropivacaine 0.1% (2 ml/kg) or 1 ml/kg of ropivacaine 0.2%.
The secondary aim of this study is to describe the pharmacokinetics of ropivacaine 0.1% and ropivacaine 0.2% after erector spinae block in children undergoing posterior spinal fusion.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
| Phase 4 |
Detailed Description
Pain is of particular concern in pediatric patients undergoing posterior spinal fusion surgery. In children, posterior spinal fusion is performed for neuromuscular or adolescent idiopathic scoliosis. Posterior spinal fusion is highly invasive and entails the fusion of multiple adjacent vertebral bodies. The surgery generates profound pain from multiple tissue sources including bones, ligaments, intervertebral discs, nerve root sleeves, fascia and muscles. In these patients, greater perioperative pain has been shown to increase the risk of chronicity, prolonged pain medication use, delayed rehabilitation and delayed return of function. Patients experiencing moderate-to-severe pain in the acute postoperative period were more likely to report higher levels of pain severity, use more pain medication, and miss a greater number of school/workdays due to back pain in the last three month.
The mainstream perioperative pain therapy in patients undergoing posterior spinal fusion is opioid-based. Prolonged intravenous opioids, however, are associate to prolonged length of stay. As a results, adjuvants of such as acetaminophen, nonsteroidal anti-inflammatory drugs and ketamine are routinely used in some centers.
Recently, the erector spinae plane (ESP) block has been proposed as an effective adjuvant in the multimodal analgesia after posterior spinal fusion .
The erector spinae plane block is a paraspinal fascial plane block in which the needle placement is between the erector spinae muscle and the thoracic transverse processes, and a local anesthetic is administered, blocking the dorsal and ventral rami of the thoracic and abdominal spinal nerves. This blockage of the dorsal and ventral rami of the spinal nerves helps to achieve a multi-dermatomal sensory block of the anterior, posterior, and lateral thoracic and abdominal walls. The erector spinae plane block has been successfully implemented in the multimodal analgesia management in both adults and children.
However, there is limited information about the pharmacokinetics of ropivacaine after erector spinae plane blocks. In adults, studies reported potentially neurotoxic plasma concentrations after the injection of a 'safe" (100 mg) dose of ropivacaine in the transversus plane. In contrast, in children, plasma concentrations of ropivacaine after ilioinguinal-iliohypogastric, transversus plane block appear to remain well below the neurotoxic blood concentration for total ropivacaine (2.2 μg/ml). Similarly, plasma concentration after erector spinae plane block have been reported to be safe, but data are limited to a single small investigation. A recent pilot study in children showed high blood concentrations (0.56 μg/L) of unbound ropivacaine exceeding its potential neurotoxic blood concentration (0.15 μg/L), but concentrations of total ropivacaine below the neurotoxic (and cardiovascular) threshold. after erector spinae plane block with ropivacaine at high concentrations (0.5%).
In 2021, at the Montreal Children's Hospital (MCH) an Enhanced recovery after surgery (ERAS) protocol for patients undergoing posterior spinal fusion was implemented. This protocol includes standardized intraoperative anesthesia and postoperative analgesia (Annex 1). At the end of the surgery, after confirming adequate spinal cord function with the motor and somatosensory evoked potentials and before skin closure, surgeon injects a 2 mg/kg dose of the local anesthetic ropivacaine 0.1% (total volume 2 ml/kg) or 0.2% (total volume 1 ml/kg) in the erector spinae plane.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Active Comparator: Ropivacaine 0.1% Erector spinae plane block with 2 ml/kg of ropivacaine 0.1%. |
Drug: Ropivacaine
Administration of Ropivacaine
|
| Experimental: Ropivacaine 0.2% Erector spinae plane block with 1 ml/kg of ropivacaine 0.2%. |
Drug: Ropivacaine
Administration of Ropivacaine
|
Outcome Measures
Primary Outcome Measures
- Opioid Consumption [24 hours after surgery]
Total opioid consumption after surgery
- Pain after surgery [24 hours after the surgery]
Severity of pain after surgery measured by heart rate variability
- Pain during surgery [During the the surgery]
Severity of pain during surgery during measured by heart rate variability
- Post-operative Complications [24 hours after the surgery]
The number of anesthesia and surgical related complications
Secondary Outcome Measures
- Secondary outcome [During the and 24 hours after the surgery]
The secondary outcome of this study is defined as the difference in rate in which of ropivacaine 0.1% and ropivacaine 0.2% is absorbed after a spinal block in children undergoing posterior spinal fusion
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Patients ≥ 8 year older and > 25 kg undergoing posterior spinal fusion surgery
-
Parents or legal guardians that are fluent in French of English
Exclusion Criteria:
-
Patients with any contraindication to locoregional anesthesia
-
Patients that are expected to be intubation for a prolonged period of time after surgery
-
Patients with anemia (hematocrit < 30%) before surgery or at time of the first study blood draw
-
Patients that do not receive an erector spinae plane block
-
Parents or legal Patient/legal guardian that to not consent to participate in the study
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- McGill University Health Centre/Research Institute of the McGill University Health Centre
Investigators
- Principal Investigator: Thomas Engelhardt, MD, PhD, McGill University Health Centre/Research Institute of the McGill University Health Centre
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 2023-9498